Table 1.
Description of study cohort and total number of samples from HIV-uninfected and in utero- and intrapartum-infected infants tested with each diagnostic assay
| Time of visit | Study cohort |
No. of samples tested with each diagnostic assayb |
||||
|---|---|---|---|---|---|---|
| Median age (wk) | Total no. of infants | No. (%) HIV infecteda | HIV DNA PCR | CAP/CTM | Aptima | |
| Birth | 0.1 | 710 | 38 (5.4) | 107 | 107 | 144c |
| 2 wk | 2.1 | 566 | 25 (4.4) | 86 | 86 | 86 |
| 4 wk | 4.6 | 556 | 25 (4.5) | 88 | 88 | 88 |
| 6 wk | 6.6 | 595 | 26 (4.4)d | 85 | 84e | 85 |
| Total | 710 | 38 (5.4) | 366 | 365 | 403 | |
In utero and intrapartum infections. HIV infection status was determined retrospectively where the routine 6-week PCR test identified an infant as HIV infected.
Samples were obtained from infants later determined to be HIV infected, together with two age-matched uninfected controls, as well as from infants who died; birth samples were also obtained from infants of an unknown status.
The screen of birth samples from infants with an unknown HIV status using the Aptima assay accounts for the additional Aptima tests.
Samples were not prepared for 2 HIV-infected infants who attended the 6-week visit.
One 6-week sample produced an invalid CAP/CTM result and could not be retested.